CD274 and neoplasm: Among the main identified predictive markers, PD-L1 expression, tumor mutation burden (TMB), tumor-infiltrating lymphocytes (TILs), neutrophil/lymphocyte ratio (NLR), and specific genetic mutations emerged as established or potential tools to tailor ICI-based strategies for NSCLC patients [65,66].